# A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM

> **NCT04198480** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 17 (estimated)

## Conditions studied

- Hypercalcemia of Malignancy

## Interventions

- **DRUG:** JMT103

## Key facts

- **NCT ID:** NCT04198480
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-24
- **Primary completion:** 2021-07-30
- **Final completion:** 2021-12-31
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2019-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04198480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04198480, "A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04198480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*